Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation - Trial NCT05556460
Access comprehensive clinical trial information for NCT05556460 through Pure Global AI's free database. This phase not specified trial is sponsored by Hangzhou Valgen Medtech Co., Ltd and is currently Not yet recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 151 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hangzhou Valgen Medtech Co., Ltd
Timeline & Enrollment
N/A
Oct 15, 2022
Oct 15, 2028
Primary Outcome
Number of patients with composite measures- All-cause death and recurrent HF hospitalizations.
Summary
To confirm the effectiveness and safety of the DragonFly-T transcatheter tricuspid valve
 repair system for the treatment of severe tricuspid regurgitation (TR) (TR grade ≥ 3+) who
 remained clinically symptomatic after guideline-directed medical treatment.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05556460
Device Trial